

Meredith S Irwin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3569747/publications.pdf>

Version: 2024-02-01

114
papers

7,745
citations

81900

39
h-index

53230

85
g-index

117
all docs

117
docs citations

117
times ranked

11347
citing authors

#	ARTICLE	IF	CITATIONS
1	Temporal clustering of neuroblastic tumours in children and young adults from Ontario, Canada. <i>Environmental Health</i> , 2022, 21, 30.	4.0	2
2	Vitamin D Receptor Activation Attenuates Hippo Pathway Effectors and Cell Survival in Metastatic Neuroblastoma. <i>Molecular Cancer Research</i> , 2022, 20, 895-908.	3.4	1
3	Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children's Oncology Group (COG) risk stratification.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10013-10013.	1.6	0
4	Abstract 5224: The PRrecision Oncology For Young peopLE (PROFYLE) Program: A national precision oncology program for children, adolescents and young adults with hard-to-cure cancer in Canada. <i>Cancer Research</i> , 2022, 82, 5224-5224.	0.9	1
5	A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28794.	1.5	29
6	Crizotinib response in a neuroblastoma patient with a constitutional mosaic anaplastic lymphoma kinase 1170N-activating mutation. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28916.	1.5	1
7	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3229-3241.	1.6	174
8	Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration. <i>Cell Reports</i> , 2021, 36, 109363.	6.4	9
9	Theranostics in Neuroblastoma. <i>PET Clinics</i> , 2021, 16, 419-427.	3.0	3
10	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 3506-3514.	1.6	38
11	Residual meta-iodobenzyl guanidine (MIBG) positivity following therapy for metastatic neuroblastoma: Patient characteristics, imaging, and outcome. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29289.	1.5	1
12	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. <i>European Journal of Cancer</i> , 2021, 157, 198-213.	2.8	34
13	Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. <i>JAMA Oncology</i> , 2021, 7, 1806.	7.1	22
14	The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors. <i>Nature Communications</i> , 2021, 12, 6274.	12.8	22
15	Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2021, 22, 1764-1776.	10.7	37
16	Veno-occlusive disease after high-dose busulfan+mephalan in neuroblastoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 531-537.	2.4	17
17	The ganglioside G _{D2} as a circulating tumor biomarker for neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28031.	1.5	30
18	The Role of Surgery in High-risk Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, 1-7.	0.6	31

#	ARTICLE	IF	CITATIONS
19	Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 895-905.	2.1	36
20	Reply to K. Beiske et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 3720-3721.	1.6	0
21	Incidence and Prognostic Role of the Ocular Manifestations of Neuroblastoma in Children. <i>American Journal of Ophthalmology</i> , 2020, 213, 145-152.	3.3	13
22	Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>European Journal of Cancer</i> , 2020, 133, 112-119.	2.8	13
23	<i>NRAS</i> Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma. <i>Cancer Research</i> , 2020, 80, 3413-3423.	0.9	40
24	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. <i>European Journal of Cancer</i> , 2020, 136, 52-68.	2.8	42
25	Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. <i>Cancer Research</i> , 2020, 80, 2663-2675.	0.9	55
26	Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. <i>Journal of Clinical Oncology</i> , 2020, 38, 1906-1918.	1.6	41
27	Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10500-10500.	1.6	2
28	Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10505-10505.	1.6	11
29	COVID-19: a pandemic experience that illuminates potential reforms to health research. <i>EMBO Molecular Medicine</i> , 2020, 12, e13278.	6.9	4
30	Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients 18 months with unfavorable histology and without MYCN amplification: A Children's Oncology Group (COG) report.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10502-10502.	1.6	0
31	Long term outcomes after concurrent ipsilateral nephrectomy versus kidney-sparing surgery for high-risk, intraabdominal neuroblastoma. <i>Journal of Pediatric Surgery</i> , 2019, 54, 1632-1637.	1.6	9
32	Tandem Transplant for High-Risk Neuroblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 729.	7.4	3
33	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. <i>Nature Communications</i> , 2019, 10, 4343.	12.8	200
34	Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 222-227.	0.6	17
35	An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27776.	1.5	16
36	Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). <i>European Journal of Cancer</i> , 2019, 112, 66-79.	2.8	49

#	ARTICLE	IF	CITATIONS
37	Current and Future Strategies for Treatment of Relapsed Neuroblastoma. , 2019, , 263-281.		1
38	Regulatory oversight for research tests and laboratory-developed diagnostics should be more nimble. Cmaj, 2019, 191, E1388-E1388.	2.0	1
39	The challenge of defining "ultra-high-risk" neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27556.	1.5	43
40	Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation. Nature Communications, 2019, 10, 224.	12.8	66
41	A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBLOOB1.. Journal of Clinical Oncology, 2019, 37, 10012-10012.	1.6	1
42	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. Journal of the National Cancer Institute, 2018, 110, 1084-1093.	6.3	73
43	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric Blood and Cancer, 2018, 65, e27023.	1.5	31
44	Characteristics and management of ganglioneuroma and ganglioneuroblastoma "intermixed" in children and adolescents. Pediatric Blood and Cancer, 2018, 65, e26964.	1.5	35
45	Autologous stem cell transplantation for refractory opsoclonus myoclonus ataxia syndrome. Pediatric Blood and Cancer, 2018, 65, e27110.	1.5	3
46	Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clinical Cancer Informatics, 2018, 2, 1-15.	2.1	20
47	Retrospective evaluation of a decision "support" algorithm (MIPOGC) for genetic referrals for children with neuroblastic tumors. Pediatric Blood and Cancer, 2018, 65, e27390.	1.5	21
48	G ₂ as a circulating tumor biomarker (CTB) for neuroblastoma (NBL).. Journal of Clinical Oncology, 2018, 36, 10538-10538.	1.6	2
49	The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients. Oncotarget, 2018, 9, 10698-10713.	1.8	0
50	Predictors of differential response to induction chemotherapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).. Journal of Clinical Oncology, 2018, 36, 10532-10532.	1.6	0
51	Pediatric oncology enters an era of precision medicine. Current Problems in Cancer, 2017, 41, 194-200.	2.0	39
52	A Metastatic Mouse Model Identifies Genes That Regulate Neuroblastoma Metastasis. Cancer Research, 2017, 77, 696-706.	0.9	28
53	Advancing Clinicopathologic Diagnosis of High-risk Neuroblastoma Using Computerized Image Analysis and Proteomic Profiling. Pediatric and Developmental Pathology, 2017, 20, 394-402.	1.0	5
54	Comprehensive Analysis of Hypermutation in Human Cancer. Cell, 2017, 171, 1042-1056.e10.	28.9	596

#	ARTICLE	IF	CITATIONS
55	Association of <i>MYCN</i> copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>Cancer</i> , 2017, 123, 4224-4235.	4.1	97
56	Target and Agent Prioritization for the Children's Oncology Group's National Cancer Institute Pediatric MATCH Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	85
57	Measuring primary tumor response in neuroblastoma: More than using a ruler. <i>Pediatric Blood and Cancer</i> , 2017, 64, 11-12.	1.5	4
58	Heterogeneity of <i>MYCN</i> amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 28-41.	2.8	34
59	Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1019-1023.	1.5	13
60	Surveillance imaging and radiation exposure in the detection of relapsed neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1786-1793.	1.5	24
61	Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1508-1515.	3.5	27
62	Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. <i>European Journal of Cancer</i> , 2016, 65, 1-10.	2.8	56
63	Transcript signatures that predict outcome and identify targetable pathways in <i>MYCN</i> -amplified neuroblastoma. <i>Molecular Oncology</i> , 2016, 10, 1461-1472.	4.6	14
64	Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in <i>TP53</i> -Associated Cancer Susceptibility. <i>Journal of Clinical Oncology</i> , 2016, 34, 3697-3704.	1.6	33
65	The neuroblastoma and ganglion components of nodular ganglioneuroblastoma are genetically similar: evidence against separate clonal origins. <i>Modern Pathology</i> , 2015, 28, 166-176.	5.5	5
66	Neuroblastoma. <i>Pediatric Clinics of North America</i> , 2015, 62, 225-256.	1.8	328
67	Bridging the Distance in the Caribbean: Telemedicine as a means to build capacity for care in paediatric cancer and blood disorders. <i>Studies in Health Technology and Informatics</i> , 2015, 209, 1-8.	0.3	15
68	Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma. <i>Oncotarget</i> , 2014, 5, 161-172.	1.8	65
69	Metastatic Neuroblastoma Confined to Distant Lymph Nodes (stage 4N) Predicts Outcome in Patients With Stage 4 Disease: A Study From the International Neuroblastoma Risk Group Database. <i>Journal of Clinical Oncology</i> , 2014, 32, 1228-1235.	1.6	28
70	Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. <i>Pediatric Blood and Cancer</i> , 2014, 61, 128-133.	1.5	31
71	Metachronous Neuroblastoma in an Infant With Germline Translocation Resulting in Partial Trisomy 2p. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e193-e196.	0.6	7
72	Spy'ing on differentiation in neuroblastoma. <i>Oncotarget</i> , 2014, 5, 5848-5849.	1.8	0

#	ARTICLE	IF	CITATIONS
73	Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1636-1641.	1.5	27
74	Clinical outcomes in children with adrenal neuroblastoma undergoing open versus laparoscopic adrenalectomy. <i>Journal of Pediatric Surgery</i> , 2013, 48, 1727-1732.	1.6	60
75	Eukaryotic Translation Elongation Factor 1-Alpha 1 Inhibits p53 and p73 Dependent Apoptosis and Chemotherapy Sensitivity. <i>PLoS ONE</i> , 2013, 8, e66436.	2.5	54
76	Current and Future Strategies for Relapsed Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 337-347.	0.6	71
77	Inhibition of SRC Corrects GM-CSF Hypersensitivity That Underlies Juvenile Myelomonocytic Leukemia. <i>Cancer Research</i> , 2013, 73, 2540-2550.	0.9	23
78	Diagnostic practices and disease surveillance in Canadian children with congenital central hypoventilation syndrome. <i>Canadian Respiratory Journal</i> , 2013, 20, 165-170.	1.6	4
79	Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) to predict outcome in patients with stage 4 disease: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10015-10015.	1.6	0
80	Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 4892-4897.	7.1	120
81	Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project. <i>European Journal of Cancer</i> , 2012, 48, 1185-1191.	2.8	14
82	Neuroblastoma: The impact of biology and cooperation leading to personalized treatments. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2012, 49, 85-115.	6.1	35
83	Long-term hepatic outcomes in survivors of stage 4S and 4 neuroblastoma in infancy. <i>Pediatric Blood and Cancer</i> , 2012, 58, 283-288.	1.5	13
84	Natural course of low risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2012, 58, 690-694.	1.5	13
85	The ribosome-related protein, SBDS, is critical for normal erythropoiesis. <i>Blood</i> , 2011, 118, 6407-6417.	1.4	30
86	NEDD8 Pathways in Cancer, Sine Quibus Non. <i>Cancer Cell</i> , 2011, 19, 168-176.	16.8	156
87	Special AT-rich Binding Protein-2 (SATB2) Differentially Affects Disease-causing p63 Mutant Proteins. <i>Journal of Biological Chemistry</i> , 2011, 286, 40671-40680.	3.4	11
88	Small Molecule Kinase Inhibitor Screen Identifies Polo-Like Kinase 1 as a Target for Neuroblastoma Tumor-Initiating Cells. <i>Cancer Research</i> , 2011, 71, 1385-1395.	0.9	92
89	Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. <i>Nature Medicine</i> , 2011, 17, 845-853.	30.7	68
90	Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. <i>EMBO Molecular Medicine</i> , 2010, 2, 371-384.	6.9	62

#	ARTICLE	IF	CITATIONS
91	SATB2 augments $\hat{\Gamma}$ Np63 $\hat{\Gamma}$ in head and neck squamous cell carcinoma. <i>EMBO Reports</i> , 2010, 11, 777-783.	4.5	50
92	<i>p53</i> family: therapeutic targets in neuroblastoma. <i>Future Oncology</i> , 2010, 6, 429-444.	2.4	18
93	Suppression of Hypoxia-Inducible Factor 2 $\hat{\Gamma}$ Restores p53 Activity via Hdm2 and Reverses Chemoresistance of Renal Carcinoma Cells. <i>Cancer Research</i> , 2009, 69, 9056-9064.	0.9	77
94	Regulation of endocytosis via the oxygen-sensing pathway. <i>Nature Medicine</i> , 2009, 15, 319-324.	30.7	178
95	In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model. <i>Neoplasia</i> , 2009, 11, 426-435.	5.3	67
96	Neuroblastoma Cells Isolated from Bone Marrow Metastases Contain a Naturally Enriched Tumor-Initiating Cell. <i>Cancer Research</i> , 2007, 67, 11234-11243.	0.9	155
97	VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail. <i>Molecular and Cellular Biology</i> , 2007, 27, 157-169.	2.3	230
98	Tissue Microenvironment Modulates CXCR4 Expression and Tumor Metastasis in Neuroblastoma. <i>Neoplasia</i> , 2007, 9, 36-46.	5.3	69
99	Overexpressed TP73 induces apoptosis in medulloblastoma. <i>BMC Cancer</i> , 2007, 7, 127.	2.6	38
100	Ubiquitin and Ubiquitin-Like Modifications of the p53 Family. <i>Neoplasia</i> , 2006, 8, 655-666.	5.3	54
101	Surgical challenges associated with intensive treatment protocols for high-risk neuroblastoma. <i>Journal of Pediatric Surgery</i> , 2006, 41, 960-965.	1.6	11
102	Analysis of needle versus open biopsy for the diagnosis of advanced stage pediatric neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2006, 47, 875-879.	1.5	29
103	$\hat{\Gamma}$ Np73: Misunderstood protein?. <i>Cancer Biology and Therapy</i> , 2006, 5, 804-807.	3.4	7
104	Mdm2-mediated NEDD8 Modification of Tap73 Regulates Its Transactivation Function*. <i>Journal of Biological Chemistry</i> , 2006, 281, 34096-34103.	3.4	94
105	Family Feud in Chemosensitivity: p73 and Mutant p53. <i>Cell Cycle</i> , 2004, 3, 317-321.	2.6	52
106	Family feud in chemosensitivity: p73 and mutant p53. <i>Cell Cycle</i> , 2004, 3, 319-23.	2.6	27
107	Chemosensitivity linked to p73 function. <i>Cancer Cell</i> , 2003, 3, 403-410.	16.8	394
108	Akt Phosphorylates the Yes-Associated Protein, YAP, to Induce Interaction with 14-3-3 and Attenuation of p73-Mediated Apoptosis. <i>Molecular Cell</i> , 2003, 11, 11-23.	9.7	723

#	ARTICLE	IF	CITATIONS
109	The Human p73 Promoter: Characterization and Identification of Functional E2F Binding Sites. <i>Neoplasia</i> , 2002, 4, 195-203.	5.3	39
110	Oncogenes Induce and Activate Endogenous p73 Protein. <i>Journal of Biological Chemistry</i> , 2001, 276, 11310-11316.	3.4	123
111	A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. <i>Nature Genetics</i> , 2000, 25, 47-54.	21.4	479
112	A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. <i>Nature</i> , 2000, 407, 642-645.	27.8	309
113	Role for the p53 homologue p73 in E2F-1-induced apoptosis. <i>Nature</i> , 2000, 407, 645-648.	27.8	656
114	Viral Oncoproteins Discriminate between p53 and the p53 Homolog p73. <i>Molecular and Cellular Biology</i> , 1998, 18, 6316-6324.	2.3	179